免疫调节治疗对老年慢性心力衰竭患者细胞因子的影响

目的 研究免疫调节治疗对老年慢性充血性心力衰竭(CHF)患者心脏功能、细胞因子的影响.方法 入选96例年龄60～78岁CHF患者,美国纽约心功能分级(NYHA)Ⅱ～Ⅳ级,抽签随机分为治疗组(常规治疗的基础上加用胸腺五肽治疗,3个疗程,共75 d)和对照组(采用常规治疗),另以45例健康老年人为健康对照组,年龄60～80岁;分别在用药前、用药第1个疗程后(第15天)、第3个疗程后(第75天)测定各组患者的左心室射血分数(LVEF)、血清炎性细胞因子肿瘤坏死因子-α(TNF-α)及白细胞介素-1β(IL-1β),血清抗炎细胞因子白细胞介素-10(IL-10)、血浆高敏C反应蛋白(hsCRP)、血浆脑钠肽(BNP),并进行明尼苏达心力衰竭生活质量评分.结果 (1)治疗前,与健康对照组比较,治疗组和对照组患者血清TNF-α、IL-1β、TNF-α与IL-10比值、血浆BNP、hCRP、明尼苏达心力衰竭生活质量评分增高(P＜0.05或P＜0.01),LVEF、血清IL-10降低(P＜0.01),治疗组和对照组两组间比较各项指标差异无统计学意义;(2)第1个疗程后与对照组比较,治疗组的血清IL-10增高(P＜0.01);血清TNF-αIL-1β、血浆BNP、hsCRP降低(P＜0.05或P＜0.01);LVEF值有增高趋势,TNF-α与IL-10比值(治疗组与对照组分别为4.84±0.53与5.28±0.66)和生活质量评分有降低趋势,但差异无统计学意义.(3)第3个疗程后,与对照组比较,治疗组的血清IL-10、LVEF值显著增高(P＜0.05或P＜0.01);血清TNF-α、IL-1β、TNF-α与IL-10比值(治疗组与对照组分别为4.55±0.69与5.18±0.38)、血浆BNP、hsCRP和生活质量评分降低(P＜0.05或P＜0.01).结论 免疫调节剂胸腺肽能够改善细胞因子失衡,进而改善心功能;免疫调节治疗为老年CHF患者提供了新的治疗途径.

Abstract：

Objective To investigate the effect of immune modulation therapy on heart function and cytokines in elder patients with chronic heart failure (CHF). Methods The 96 patients aged 60-78 years with New York Heart Association(NYHA)functional. class Ⅱ-Ⅳ CHF were randomly divided into two groups: CHF treatment group received regular therapy and thymopetidum and CHF control group received regular therapy. Another 45 healthy individuals aged 60-80 years were involved as normal control. The ejection faction of left ventricle (LVEF), inflammatory cytokines including tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), anti-inflammatory cytokine interleukin-10 (IL-10), plasma high sensitive C-reactive protein (hsCRP), plasma brain natrium peptide (BNP)and Minnesota Living with Heart Failure Questionnaire (LHFQ) assessment were tested before therapy, 15 days and 75 days after treatment. Results (1) Before therapy, compared with normal control group, the levels of TNF-α, IL-1β, TNF-α/IL-10 ratio, BNP, hsCRP and LHFQ were significantly increased (P ＜ 0. 05 or P ＜ 0. 01 ), and the levels of IL-10, LVEF were markedly decreased (P＜0.01) in the patients of CHF treatment group and CHF control group. While no difference between the two CHF groups was observed. (2) After the first course of treatment,compared with CHF control group, the levels of IL-10 were increased (P＜0. 01), while the levels of TNF-α, IL-1β, BNP and hsCRP were decreased (P＜0.05 or P＜0.01) in CHF treatment group. The level of LVEF was increased, TNF-α/IL-10 ratio (4.84 ±0. 53 vs. 5.28±0. 66) and LHFQ were decreased even though there was no significant difference between the two groups. (3) After the second course of treatment, compared with CHF control group, the levels of IL-10 and LVEF were increased (P＜0. 05 or P＜0.01), while the level of TNF-α, IL-1β, TNF-α/IL-10 ratio (4.55±0. 69 vs. 5.18±0.38), BNP, hsCRP and LHFQ were decreased (P＜0.05 or P＜0.01) in CHF treatment group. Conclusions Thymopetidum, as an immunemodulating agent, might regulate the equilibrium of cytokines and improve the heart function of patients with CHF, indicating that immune modulation therapy might improve the treatment strategy for CHF patients.     

脑钠肽联合组织多普勒检查对老年高血压患者左室肥厚及舒张功能受损的评估

目的 探讨老年原发性高血压患者左室肥厚(LVH)及舒张功能与脑钠肽(BNP)水平的关系.方法 140例老年原发性高血压患者,其中左室肥厚(LVH)组69例,非左室肥厚(NLVH)组71例,健康对照组50例.测定各组BNP浓度.常规脉冲多普勒测量二尖瓣口舒张早期血流速度(E)、舒张晚期血流速度(A),计算E/A值.应用定量组织速度成像(QTVI)技术测量左室壁二尖瓣环6个位点(侧壁和后间隔、前壁和下壁、前间隔和后壁)处的舒张早期峰值运动速度(Em)、舒张晚期峰值运动速度(Am),计算Em/Am值,同时计算6个位点平均速度(MEm、MAm)、MEm/MAm值及E/MEm值.比较3组间舒张功能指标的变化,以及BNP浓度与超声指标的关系.结果 高血压NLVH组、LVH组E/MEm(11.3±1.83、15.7±1.45)及BNP浓度[(61.64±37.18)ng/L、(138.65±30.23)ng/L]较对照组升高(P＜0.05及P＜0.01);MEm[(6.32±0.94)cm/s、(4.29±0.91)cm/s]及MEm/MAm值(0.76±0.19、0.51±0.11)较对照组减低(P＜0.05及P＜0.01);高血压组BNP浓度与E/A、MEm、MEm/MAm值显著负相关(r=-0.294、r=-0.387、r=-0.422,均P＜0.01),与LVMI及E/MEm值显著正相关(r=0.342及r=0.501,均P＜0.01).结论 高血压患者无论有无左室肥厚均有舒张功能减低,而LVH患者左室舒张功能障碍更为严重.联合血浆BNP浓度和超声指标有助于准确评估老年高血压患者左室肥厚和舒张功能.

Abstract：

Objective To investigate the clinical values of brain natriuretic peptide (BNP) in combination with TDI in diagnosing left ventricular hypertrophy (LVH) and impaired diastolic function in elderly hypertensive patients. Methods The 140 elderly hypertensive patients were divided into LVH group (n=69) and NLVH group (n=71). Control group consisted of 50 normal subjects. Plasma BNP level and index of echocardiography, including mitral peak flow velocity during early and late diastole (E, A), ratio of E/A, average peak velocities of six LV wall sites at mitral annuluses during early and late diastole (MEm, MAm), ratios of MEm/MAm and E/MEm were measured in all patients. The correlation of plasma BNP level with cardiac ultrasonographic findings was also examined. Results The level of BNP [(61.64±37.18)ng/L, (138. 65±30. 23)ng/L] and the ratio of E/MEm (11.3±1.83, 15.7±1.45) were significantly higher in NLVH group and LVH group than in normal group (P＜0. 05 or P＜0. 01). MEm [(6.32±0. 94)cm/s, (4.29±0. 91)cm/s]and MEm/MAm (0.76±0.19, 0.51±0. 11) were significantly lower in NLVH and LVH group than in normal group (P＜0.05 or P＜0. 01). The BNP level was negatively correlated with E/A, MEm and MEm/MAm (r=- 0. 294, r= 0. 387 and r= 0. 422, all P＜0. 01), and was positively correlated with LVMI and E/MEm (r=0.342, r=0.501, all P＜0.01). Conclusions Left ventricular diastolic function is impaired in elderly hypertension patients regardless of LVH or NLVH.Plasma BNP level in combination with echocardiography parameter is accurate to evaluate the LVHand impaired diastolic function in elderly hypertensive patients.     

血浆甘露聚糖结合凝集素与类风湿关节炎肾损害的相关性研究

目的 检测类风湿关节炎(RA)相关性肾损害患者甘露聚糖结合凝集素(MBL)的血浆水平,探讨MBL在RA相关肾损害中可能的作用机制.方法 用酶联免疫吸附试验(ELISA)法检测19例RA相关肾损害患者、49例RA不伴肾损害患者及40名健康对照者的血浆MBL水平,并收集RA患者临床资料及相关实验室检查资料进行对比分析.采用x2检验、t检验和Spearman相关分析进行统计学处理.结果 较无肾损害组比,RA相关肾损害组患者肿胀压痛关节数增多[(15±9)和(9±11)个],晨僵时间延长[(2.9±1.3)和(2.3±1.6)h],其他(除肾脏)关节外伴随症状发生率明显升高[(42.1%和16.3%),P＜0.01或P＜0.05];但二组间RA病程、关节畸形的发生率差异无统计学意义(P＞0.05);RA相关肾损害组血小板(PLT)[(376±155)×109/L和(304±121)×109/L]、循环免疫复合物(CIC)[(4.3±3.0)和(2.9±3.3)g/L]、红细胞沉降率(ESR)[(79±46)和(53±31)mm/1 h]、类风湿因子(RF)[(77±42)和(52±49)U/ml]、C反应蛋白(CRP)[(32±28)和(23±18)mg/L]、免疫球蛋白IgG[(11.7±2.6)和(8.4±2.4)g/L]、补体C3[(1.18±0.53)和(0.94±0.21)g/L]高于RA无肾损害组(P＜0.01或P＜0.05),血浆白蛋白(Alb)[(26±13)比(30±9)g/L]低于无肾损害组(P＜0.05);二组RA患者血浆MBL水平均较对照组血浆MBL水平[(3.1±0.5)mg/L]显著下降(P＜0.01),RA相关肾损害组MBL水平[(1.7±1.2)mg/L]较无肾损害组MBL水平[(1.4±1.3)mg/L]升高(P＜0.05);RA相关肾损害组MBL与IgG、C3、CRP、尿蛋白定量(24 h)呈正相关(r分别为0.6,0.6,0.47,0.57;P＜0.05).结论 RA相关肾损害与免疫复合物相关;RA相关肾损害患者血浆MBL水平是升高的,血浆中高水平MBL可能是RA相关肾损害的发病机制之一.

Abstract：

Objective To detect the serum level of mannose binding lectin (MBL) in patients with renal injury induced by rheumatoid arthritis (RA), and to investigate the role of MBL in the pathogenesis of renal injury in RA. Methods ELISA was used to measure the serum MBL level of 19 RA patients with renal injury, 49 RA patients without renal injury and 40 healthy individuals. The clinical features and laboratory markers were compared and analyzed by chi-square test, two independent samples t-test and Spearman's correlation analysis. Results Compared with RA patients without renal injury, the number of tender and swollen joints [(15±9) vs (9±11)], duration of morning stiffness [(2.9±1.3) vs (2.3±1.6) h] and extraarticular manifestations (42.1％ vs 16.3％) in RA patients with renal injury were significantly higher (P＜0.05or P＜0.01). There was no significant difference between the two groups in RA disease duration and jointdeformity(P＞0.05). In patients with renal injury, the level of platelet count [(376±155)×109/L vs (304±121)×109/L], CIC[(4.3±3.0) vs (2.9±3.3) g/L], ESR[(79±46) vs (53±31) mm/1 h], RF[(77±42) vs (52±49)U/ml], CRP[(32±28)vs (23±18)mg/L], IgG[(11.7±2.6)vs (8.4±2.4)g/L], C3[(1.18±0.53)vs (0.94±0.21) g/L] were higher than those in RA patients without renal injury (P＜0.01 or P＜0.05); the level of Alb [(26±13) vs (30±9) g/L] was lower than that in RA patients without renal injury (P＜0.05). The level of serum MBL in the two groups of RA patients was significantly lower than that in the healthy group [(3.1±0.5)mg/L](P＜0.01), and the level of serum MBL in RA patients with renal injury [(1.7±1.2) mg/L] was higher than that in RA patients without renal injury [(1.4±1.3) mg/L](P＜0.05). The level of serum MBL in RA patients with renal injury showed a positive correlation with IgG, C3, CRP and 24 h urine protein level (r=0.6, 0.6, 0.47, 0.57; P＜0.05). Conclusion Renal injury in RA patients is immune complex dependent. The serum level of MBL is higher in patients with renal injury, therefore, high-concentration MBL may be one of a potential causes of renal injury in RA patients.     

Prognosticvalueofincreasedcarbohydrateantigeninpatientswithheart failure

AIM:To study the prognostic value of carbohydrateantigen 125(CA125) and whether it adds prognostic information to N-terminal pro-brain natriuretic peptide(NT-proBNP) in stable heart failure(HF) patients.METHODS:The predictive value of CA125 was retrospectively assessed in 156 patients with stable HF remitted to the outpatient HF unit for monitoring from 2009 to 2011.Patients were included in the study if they had a previous documented episode of HF and received HF treatment.CA125 and NT-proBNP concentrations were measured.The independent association between NT-proBNP or CA125 and mortality was assessed with Cox regression analysis,and their combined predictive ability was tested by the integrated discrimination improvement(IDI) index.RESULTS:The mean age of the 156 patients was 72 ± 12 years.During follow-up(17 ± 8 mo),27 patients died,1 received an urgent heart transplantation and 106 required hospitalization for HF.Higher CA125 values were correlated with outcomes:58 ± 85 KU/L if hospitalized vs 34 ± 61 KU/L if not(P 0.05),and 94 ± 121 KU/L in those who died or needed urgent heart transplantation vs 45 ± 78 KU/L in survivors(P 0.01).After adjusting for propensity scores,the highest risk was observed when both biomarkers were elevated vs not elevated(HR = 8.95,95%CI:3.11-25.73; P 0.001) and intermediate when only NT-proBNP was elevated vs not elevated(HR = 4.15,95%CI:1.41-12.24; P 0.01).Moreover,when CA125 was added to the clinical model with NT-proBNP,a 4%(P 0.05) improvement in the IDI was found.CONCLUSION:CA125 60 KU/L identified patients in stable HF with poor survival.Circulating CA125 level adds prognostic value to NT-proBNP level in predicting HF outcomes.     

血清糖类抗原125水平对慢性心衰患者的辅助诊断价值

目的:研究血清糖类抗原125(CA125)水平对慢性充血性心力衰竭(CHF)患者病情的辅助诊断价值。方法:2014年2月~2015年2月我院确诊为CHF的患者147例按NYHA分级标准被分为3组:心功能Ⅱ级组(61例)、Ⅲ级组(48例)和Ⅳ级组(38例),同期在本院体检的心功能正常者(NYHA I级)45例作为正常对照组,检测各组患者血清CA125、CA199、癌胚抗原(CEA)、B型脑钠肽(BNP)水平及左心室射血分数(LVEF),并进行比较;将CA125水平与BNP水平、LVEF进行相关性分析。结果:4组患者血清CA125、BNP水平差异有统计学意义(P0.05或0.01)。与心功能Ⅰ级和Ⅱ级组比较,心功能Ⅲ级和Ⅳ级组患者CA125水平[(21.97±15.33)U/ml、(24.74±16.60)U/ml比(43.08±26.75)U/ml、(62.52±51.27)U/ml]明显升高,且心功能Ⅳ级明显高于Ⅲ级组(P0.05或0.01);BNP水平随着心功能等级的提升而明显升高[(49.52±22.14)pg/ml比(189.46±63.95)pg/ml比(436.29±165.78)pg/ml比(685.41±302.08)pg/ml],P均0.01,LVEF随心功能级别升高而显著下降(P0.05或0.01)。Pearson相关分析显示,CA125水平与BNP水平呈正相关(r=0.57,P0.05)。结论:血清糖类抗原125水平可以反映慢性心力衰竭患者病情的严重程度,具有一定的辅助诊断价值。     

Adrenomedullin in cirrhotic and non-cirrhotic portal hypertension

AIM:Adrenomedullin (ADM) is a potent vasodilator peptide.ADM and nitric oxide (NO) are produced in vascular endothelial cells. Increased ADM level has been linked to hyperdynamic circulation and arterial vasodilatation in cirrhotic portal hypertension (CPH). The role of ADM in non-cirrhotic portal hypertension (NCPH) is unknown, plasma ADM levels were studied in patients with NCPH, compensated and decompensated cirrhosis in order to determine its contribution to portal hypertension (PH) in these groups.METHODS: There were 4 groups of subjects. Group 1consisted of 27 patients (F/M: 12/15) with NCPH due to portal and/or splenic vein thrombosis (mean age: 41±12years), group 2 consisted of 14 patients (F/M: 6/8) with compensated (Child-Pugh A) cirrhosis (mean age: 46±4),group 3 consisted of 16 patients (F/M: 6/10) with decompensated (Child-Pugh C) cirrhosis (mean age: 47±12).Fourteen healthy subjects (F/M: 6/8) (mean age: 44±8) were used as controls in Group 4. ADM level was measured by ELISA. NO was determined as nitrite/nitrate level by chemoluminescence.RESULTS: Adl level in Group 11 (236±61.4 pg/mL) was significantly higher than that in group 2 (108.4±28.3 pg/mL)and group 4 (84.1±31.5 pg/mL) (both P＜0.0001) but was lower than that in Group3 (324±93.7 pg/mL) (P=0.002). NO level in group 1 (27±1.4 μmol/L) was significantly higher than that in group 2 (19.8±2.8 μmol/L) and group 4 (16.9±1.6μmol/L) but was lower than that in Group 3 (39±3.6 μmol/L)(for all three P＜0.0001). A strong correlation was observed between ADM and NO levels (r=0.827, P＜0.0001).CONCLUSION: Adrenomedullin and NO levels were high in both non-cirrhotic and cirrhotic portal hypertension and were closely correlated, Adrenomedullin and NO levels increased proportionally with the severity of cirrhosis, and were significantly higher than those in patients with NCPH.Portal hypertension plays an important role in the increase of ADM and NO. Parenchymal damage in cirrhosis may contribute to the increase in these parameters.     

重组人脑利钠肽和硝普钠治疗老年人慢性充血性心力衰竭急性期的疗效对照研究

目的 比较重组人脑利钠肽(rhBNP)和硝普钠治疗老年人慢性充血性心力衰竭(CHF)急性期的临床疗效,对心功能、血清脑利钠肽(BNP)、去甲肾上腺素(NE)、内皮素-1(ET-1)及抗利尿激素(ADH)水平的影响.方法 89例年龄65～85岁的CHF急性期患者随机分为rhBNP组(47例)和硝普钠组(42例),观察两组患者治疗前、后的临床疗效、心功能的变化和血清BNP、NE、ET-1及ADH水平的变化.结果 rhBNP组显效率51.1%(24例),总有效率95.7%(45例),均高于硝普钠组,分别为26.2%(11例)及66.7%(28例),差异有统计学意义(P＜0.05和P＜0.01);无效率4.3%(2例),低于硝普钠组33.3%(14例),差异有统计学意义(P＜0.01);rhBNP组死亡1例,硝普钠组死亡3例;rhBNP组治疗后2周左心室射血分数值较治疗前升高,分别为(46.2±9.5)%与(38.1±6.0)%,差异有统计学意义(P＜0.05);rhBNP组治疗后2周血清BNP水平较硝普钠组下降(P＜0.05);rhBNP组治疗后24 h及治疗后2周血清BNP、NE均较基线值下降(P＜0.01),治疗后2周较治疗后24 h进一步降低(P＜0.01);rhBNP组治疗后2周血清ET-1水平较硝普钠组下降(P＜0.05),rhBNP组治疗后24 h血清ET-1与基线值比较差异无统计学意义(P＞0.05),但治疗后2周较基线值及治疗后24 h下降(均P＜0.01);两组治疗前、治疗后24 h及治疗后2周血清ADH水平比较差异均无统计学意义(P＞0.05),rhBNP组发生头痛2例(4.3%),低血压7例(14.9%),均低于硝普钠组[分别为8例(19.0%)及10例(23.8%)],差异有统计学意义(P＜0.05).结论 rhBNP能明显改善CHF急性期患者心室收缩功能,拮抗神经-内分泌激素的过度激活,可安全、有效用于老年CHF患者急性期的治疗.

Abstract：

Objective To compare the curative effects between recombinant human brain natriuretic peptide (rhBNP) and sodium nitroprusside in treatment of the acute attack of elderly patients with chronic heart failure (CHF), and probe the impacts of rhBNP on the heart function,serum B-type natriuretic peptide (BNP), norepinephrine (NE), endothelin 1 (ET-1) and antidiuretic hormone (ADH) levels. Methods The 89 patients aged 65-85 years at acute attack stage of CHF were randomized into two therapy groups: rhBNP group (n= 47) and sodium nitroprusside group (n=42). The clinical effects, heart function, serum BNP, NE, ET-1 and ADH changes were observed before and after the treatment. Results After 24 hours of treatment, the efficacy rate and total effective rate were higher in rhBNP group than in sodium nitroprusside group (51.1% vs. 26.2 %,95.7% vs. 66. 7%, respectively, P＜0. 05 and P＜0. 01), and non-efficacy rate in rhBNP group was lower (4.3% vs. 33. 3%, P＜0. 01). There was one death case in rhBNP group and three in sodium nitroprusside group. In rhBNP group, left ventricular ejection fraction values increased after 2 weeks of treatment [(46.2± 9.5)% vs. (38.1 ±6.0)%], P＜0.05. Serum BNP level significantly decreased in rhlBNP group than in sodium nitroprusside group after 2 weeks of treatment (P＜0.05).In rhBNP group, serum BNP and NE levels decreased 24 hours and 2 weeks after treatment (P＜0. 01) and the levels furtherly reduced after 2 weeks (P＜0.01). Serum ET-1 level decreased in rhBNP group than in sodium nitroprusside group 2 weeks after treatment (P＜0.05). In rhBNP group, there was no significant difference in serum ET-1 level between baseline and 24 hours after treatment (P＞ 0. 05), but the ET-1 level decreased 2 weeks after treatment as compared with 24 hours after treatment (P＜0.01). There were no significant differences between the two groups before and after treatment (P＞0.05). Incidences of headache and hypotension were lower in rhBNP group than in sodium nitroprusside group (4.3% vs. 19.0%, 14.9% vs. 23.8%, both P＜0.05),Conclusions RhBNP can be safely and effectively used for acute attack of CHF.     

老年急性心肌梗死患者B型利钠肽和超敏C反应蛋白检测分析

Objective To explore the clinical significance of determination of the serum levels of brain (B-type) natriuretic peptide (BNP) and high-sensitivity C-reactive protein (hs-CRP) in patients with acute myocardial infarction (AMI).Methods The clinical data of 60 cases with AMI and 50healthy controls were analyzed retrospectively.The BNP and hs-CRP levels were analyzed in AMI and Killip class,and their relationship with prognosis was investigated.Results The serum levels of BNP,hs-CRP and creatine kinase (CK)-MB) were higher in AMI group than in control group (all P＜0.05),and the levels were lowered after treatment (P＜0.05).The correlation analysis indicated that BNP and hs-CRP had positive correlations with CK-MB (r=0.892 and 0.683,all P＜0.05),and increased along with the severity of Killip classification.The 8 cases (13.3 % ) died,and single factor analysis revealed that BNP (≥56.1 pmol/L),hs-CRP (≥9.0 mg/L),CK-MB (≥75.1 U/L) and Killip classification (grade Ⅲ and Ⅳ) were the poor prognostic factors (P＜0.05).Conclusions The elevation of BNP and hs-CRP level is correlated with the severity of AMI,and could be used to evaluate the AMI patients' diagnosis and prognosis.     

老年急性心肌梗死患者B型利钠肽和超敏C反应蛋白检测分析

Objective To explore the clinical significance of determination of the serum levels of brain (B-type) natriuretic peptide (BNP) and high-sensitivity C-reactive protein (hs-CRP) in patients with acute myocardial infarction (AMI).Methods The clinical data of 60 cases with AMI and 50healthy controls were analyzed retrospectively.The BNP and hs-CRP levels were analyzed in AMI and Killip class,and their relationship with prognosis was investigated.Results The serum levels of BNP,hs-CRP and creatine kinase (CK)-MB) were higher in AMI group than in control group (all P＜0.05),and the levels were lowered after treatment (P＜0.05).The correlation analysis indicated that BNP and hs-CRP had positive correlations with CK-MB (r=0.892 and 0.683,all P＜0.05),and increased along with the severity of Killip classification.The 8 cases (13.3 % ) died,and single factor analysis revealed that BNP (≥56.1 pmol/L),hs-CRP (≥9.0 mg/L),CK-MB (≥75.1 U/L) and Killip classification (grade Ⅲ and Ⅳ) were the poor prognostic factors (P＜0.05).Conclusions The elevation of BNP and hs-CRP level is correlated with the severity of AMI,and could be used to evaluate the AMI patients' diagnosis and prognosis.     

血管性血友病因子和ADAMTS-13水平与急诊冠状动脉支架置入术后冠状动脉血流的关系

目的 探讨急性ST段抬高型心肌梗死(STEMI)患者血浆血管性血友病因子(vWF)和其裂解酶ADAMTS-13水平与急诊冠状动脉支架置入术后冠状动脉心肌梗死溶栓试验(TIMI)血流的关系.方法 根据支架释放后即刻造影显示的TIMI血流情况,将2007年9月至2009年12月期间在我院行急诊冠状动脉支架置入术的STEMI患者分为TIMI≤2级组(最终入选43例)和TIMI 3级组(最终入选43例),并选择同期冠状动脉造影正常的胸闷、胸痛患者作为阴性对照组(43例).采用双抗体夹心酶联免疫吸附法(ELISA)分别在入院即刻、冠状动脉介入术开始即刻以及介入术后1周检测患者外周血vWF和ADAMTS-13水平.结果 在不同时间TIMI≤2级组和TIMI 3级组血浆vWF水平均显著高于阴性对照组(均P＜0.05).TIMI≤2级组血浆vWF水平在不同时间均显著高于T1MI 3级组[分别为入院即刻(6721.83±1380.58)U/L比(4786.12±2362.01)U/L,P＜0.05;介入术开始即刻(5744.65±1240.71)U/L比(3011.33±2270.40)U/L,P＜0.05;介入术后1周(2001.48±931.70)U/L比(1365.17±724.12)U/L,P＜0.05].3组患者入院即刻和介入术开始即刻血浆ADAMTS-13水平差异无统计学意义.术后1周TIMI ≤2级组ADAMTS-13水平明显高于TIMI 3级组[(406.93±101.44)mg/L比(270.34±115.12)mg/L,P＜0.05].logistic回归分析表明,入院即刻vWF水平(OR:1.917,P＜0.01)和介入术开始即刻vWF水平(OR:2.016,P＜0.01)均是影响支架术后冠状动脉TIMI血流的危险因素.结论 STEMI患者急诊支架术后冠状动脉TIMI血流状况与患者术前血浆vWF水平有关,vWF与ADAMTS-13的失衡可能是急诊支架置入术后冠状动脉血流缓慢的原因之一.

Abstract：

Objective To investigate the relationship between post-stenting coronary thrombolysis in myocardial infarction (TIMI) flow and plasma von Willebrand factor (vWF) and its cleaving protease(ADAMTS-13) levels in patients with ST segment elevation myocardial infarction (STEMI). Methods STEMI patients who underwent primary percutaneous coronary intervention ( PCI ) and stenting between September, 2007 and December, 2009 were enrolled. According to the post-stenting TIMI flow, patients were divided to TIMI≤2 group (n =43) and TIMI 3 group (n =43). Patients with chest pain or dyspnea and normal coronary angiographic results served as control group ( n = 43 ). The levels of vWF and ADAMTS-13 were measured by ELISA at three time points: immediatly after admission, beginning of PCI and 1 week after PCI. Results Levels of vWF in STEMI patients at all 3 time points were significantly higher than in control patients, and the level of vWF was significantly higher in TIMI ≤2 group than in TIMI 3 group [at admission: (6721.83 ± 1380.58) U/L vs. (4786. 12 ±2362.01) U/L, P ＜0.05; at the beginning of PCI: (5744.65 ±1240. 71) U/L vs. (3011.33 ±2270.40) U/L, P＜0. 05 and at 1 week after PCI: (2001.48 ± 931.70) U/L vs. ( 1365. 17 ± 724. 12 ) U/L, P ＜ 0. 05]. ADAMTS-13 levels were similar among groups at admission and at beginning of PCI, however, the level of ADAMTS-13 at 1 week after PCI was significantly higher in TIMI≤2 group than that in TIMI 3 group [(406. 93 ± 101.44 )mg/L vs. ( 270. 34 ± 115.12) mg/L, P ＜0. 001]. Logistic regression analysis showed that both vWF at admission(OR=1.917, P＜0.01) and vWF at the beginning of PCI (OR=2.016, P＜0. 01) were risk factors of TIMI≤2. Conclusion Increased vWF during peri-PCI periods was associated with post-stenting coronary TIMI ≤2 after primary PCI in STEMI patients, and the imbalance between vWF and ADAMTS-13 may thus play an important role in the development of slow flow post PCL     

外周血清CA125水平对慢性心力衰竭患者再住院率的预测价值

目的探讨外周血清糖类抗原125（CA125）水平对慢性心衰（CHF）患者再住院率的预测价值。方法145例慢性心衰患者根据心功能NYHA分级标准分为Ⅰ／Ⅱ、Ⅲ、Ⅳ级三组,比较各组CA125和B型钠尿肽（BNP）水平。根据不同外周血清CA125、BNP水平分组,随访1～6个月,以死亡或再住院为终点事件,分析不同外周血清CA125、BNP水平慢性心衰患者的再住院率。结果血清CA125水平随NYHA心功能分级增高而增高[Ⅰ／Ⅱ级（18．79±5．23）U／ml,m级（82．34±24．37）U／ml,Ⅳ级（187．40±37．42）U／ml,P〈0．05];慢性心衰患者再住院率随CA125水平增高而增高（P=0．011）,随BNP水平增高而增高（P=0．001）。CA125联合BNP对慢性心衰患者再住院率的预测价值更好（P=0．00012）。结论血清CA125水平不仅能反映心衰的严重程度,还能反映慢性心衰患者的预后。     

血浆BNP及CRP水平在充血性心衰与肺心病患者的动态变化

目的:探讨血浆脑钠肽(BNP)及C反应蛋白(CRP)水平在充血性心力衰竭(CHF)及肺源性心脏病(PHD)患者急性呼吸困难发作时及缓解后1周的变化并分析其临床意义。方法:入选CHF患者55例(CHF组),PHD患者47例(PHD组),分别测定各组患者急性呼吸困难发作时及缓解后1周血浆BNP及CRP水平。结果:与呼吸困难发作时比较,病情缓解后1周CHF患者血浆BNP[(1885±745)ng/L比(207±124)ng/L]、CRP[(36±11)mg/L比(8±6)mg/L]水平均明显下降,P均<0.05;PHD患者血浆BNP[(584±178)ng/L比(162±59)ng/L]、CRP水平亦均明显下降[(68±24)mg/L比(15±7)mg/L],P<0.05;呼吸困难发作时CHF组患者血浆BNP水平明显高于PHD组(P<0.05),CRP水平明显低于PHD组(P<0.05),呼吸困难缓解后1周两组间无显著差异。结论:脑钠肽及C反应蛋白水平与充血性心力衰竭及肺源性心脏病患者病情严重程度相关,在发作急性呼吸困难时检测二者水平有助于鉴别充血性心力衰竭或肺源性心脏病。     

心力衰竭患者血红蛋白水平与神经内分泌细胞因子关系及对心室重构的影响

目的 探讨慢性心力衰竭(CHF)患者血红蛋白(Hb)水平变化与神经内分泌激素、细胞因子和B型钠尿肽(BNP)的关系及对心室重构的影响.方法 对入选的121例CHF患者测定Hb、血管紧张素Ⅱ(Ang Ⅱ)、肿瘤坏死因子(TNF)-α、一氧化氮(NO)、细胞间黏附分子(ICAM)-1、BNP水平,超声心动图测量左室射血分数(LVEF),评价心功能,计算左心室质量指数(LVMI)和平均室壁应力(MWS);CHF患者按Hb水平分为贫血组和非贫血组.同时选择27例健康人为对照组.结果 CHF组患者AngⅡ、TNF-α、NO和ICAM-1、BNP水平以及LVMI和MWS高于对照组(均为P＜0.01),而Hb水平和LVEF低于对照组;随着Ang Ⅱ、TNF-α、NO、ICAM-1、BNP水平以及MWS和LVMI升高,Hb水平逐渐降低,心功能指标下降;CHF贫血组Ang Ⅱ、TNF-α、NO、ICAM-1、BNP水平及MWS和LVMI高于非贫血组,分别[为(144.5±64.1)ng/L与(76.7±48.5)ng/L、(92.3±6.4)ng/L与(55.6±10.2)ng/L、(65.2±4.2)μmol/L与(42.1±11.9)μmol/L、(253.6±26.0)μg/L和(237.2±33.3)μg/L、(1294.0±223.0)ng/L与(437.0±115.0)ng/L、P＜0.01];随着AngⅡ、TNF-α、NO、ICAM-1、BNP水平以及MWS和LVMI进一步升高,CHF患者贫血程度加重;CHF患者Hb与AngⅡ、TNF-α、NO、ICAM-1、BNP水平及LVMI和MwS均呈负相关(r分别为-0.8173、-0.8509、-0.6001、-0.6692、-0.6283、-0.8604、-0.8733,P＜0.01).结论 CHF患者神经内分泌激素激活、细胞因子过度表达参与了心室重构和贫血发生发展的病理过程,而贫血使心室重构程度加重.     

Serum carbohydrate antigen 125 levels in nonischemic dilated cardiomyopathy: a useful biomarker for prognosis and functional mitral regurgitation

The authors investigated the prognostic relevance of serum carbohydrate antigen 125 (CA125) levels in nonischemic dilated cardiomyopathy (NICMP) and assessed whether increased levels relate to the degree of functional mitral regurgitation (FMR). Seventy-seven patients with NICMP were enrolled and followed-up for 10 ± 2 months in this prospective study. Receiver-operating characteristic analysis established a cutoff CA125 value of 25 U/mL for predicting mortality. Patients were divided into two groups according to their CA125 levels (CA125 <25 U/mL [n=58] and CA125 ≥ 25 U/mL [n=19]). Patients with high CA125 values had statistically worse functional status, higher B-type natriuretic peptide (BNP) levels, higher left ventricular volumes, lower ejection fraction, higher E/Em ratio, higher pulmonary artery systolic pressure, and more severe FMR. On the multivariate analysis, serum CA125 (P=.002) and severe FMR (P=.04) were identified as the independent predictors of mortality. Serum CA125 levels also correlated with BNP levels and FMR severity (P<.001). Serum CA125 is a powerful prognostic biomarker that is associated with the severity of heart failure, serum BNP levels and several echocardiographic parameters including left ventricular volumes, systolic and diastolic functions, pulmonary artery pressure, and the degree of FMR. Serum CA125 was also shown as an independent predictor of mortality during 10 ± 2 months of follow-up.     

老年上皮性卵巢癌患者血清人附睾上皮分泌蛋白4的变化及临床意义

目的 探讨老年上皮性卵巢癌患者血清中人附睾上皮分泌蛋白4(human epididymis protein 4,HE4)的改变及其临床意义.方法 用ELISA法检测老年上皮性卵巢癌33例、良性卵巢疾病17例及老年健康女性20例血清HE4水平,另选同期非老年上皮性卵巢癌患者31例及健康女性20例为对照,同时测定糖类抗原125(CA125).结果 健康人群中≥60岁组血清HE4水平(32.25±13.15)pmol/L高于＜60岁组(24.59±8.60)pmol/L,血清HE4水平与年龄呈显著正相关(r=0.525,P＜0.01).老年组中上皮性卵巢癌患者血清HE4水平明显高于卵巢良性疾病患者(中位数81.50 pmol/L对45.60 pmol/L,U=168.5,P＜0.05)和健康对照者(中位数81.50 pmol/L对33.30 pmo1/L,U=76.5,P＜0.01);根据受试者操作特性曲线(ROC曲线)分析,HE4检测老年上皮性卵巢癌的临界值为65.43 pmol/L时,其敏感度为66.67%,特异性为86.49%,与CA125相比曲线下面积为0.799比0.782,HE4诊断价值稍高于CA125;老年与非老年上皮性卵巢癌患者血清HE4水平比较,差异无统计学意义(U=404.2,P＞0.05).结论 年龄是影响人血清HE4水平的重要生理因素,HE4测定有助于老年人上皮性卵巢癌的诊断,与CA125联合检测,可显著提高诊断的准确性.     

慢性重度心力衰竭患者血B型利钠肽浓度正常的临床意义探讨

目的 探讨慢性重度心力衰竭(心衰)患者出现血B型利钠肽(B-type natriuretic peptide,BNP)浓度正常的临床意义.方法 采用前瞻性对照研究的方法观察心功能Ⅲ～Ⅳ级的慢性重度心衰患者57例.血BNP浓度正常的13例患者为研究组(A组),血BNP浓度明显升高的44例为对照组(B组),分析两组患者的临床特点,判定血BNP浓度正常对于慢性重度心衰患者的意义.结果 两组患者的基线情况差异无统计学意义.A组的左室舒张末期内径大于B组[(70.56±4.33)mm与(63.73±3.75)mm,P＜0.05];A组的左室射血分数小于B组[(24.16±2.50)%与(28.49±2.63)%,P＜0.05].A组中能耐受美托洛尔的人数比例少于B组[(7/13)与(39/44),P＜0.05],耐受剂量低于B组[(12.5±6.25)mg/d与(24.20±11.22)mg/d,P＜0.05].两组血BNP浓度在稳定期各时间段无明显改变,但在慢性心衰急性发作与缓解后,A组无显著性改变[(74.03±11.18)ng/L与(71.38±11.68)ng/L,P＞0.05],而B组改变明显[(962.73±165.00)ng/L与(876.24±167.70)ng/L,P＜0.05].随访中,A组病死率高于B组(11/13与6/44,P＜0.05).Logistic多因素回归分析显示:血BNP降低为预测重度慢性心衰患者心原性死亡的独立危险因素(OR值45.488,95%可信区间5.322～388.791),P＜0.05.结论 慢性重度心衰患者出现血BNP浓度正常提示BNP分泌机制的耗竭和心脏功能的进一步恶化.     

冠心病患者血清CA125与心功能及细胞因子的相关性

目的:研究冠心病患者血清CA125水平与心功能及细胞因子的相关性。方法:选择136例冠心病患者(CHD组),根据症状分为稳定型心绞痛(SAP)组(82例)和不稳定型心绞痛(UAP)组(54例),根据血管狭窄数目分为单支病变组(41例)、双支病变组(46例)和多支病变组(49例),按NYHA心功能分级标准分为Ⅰ级(31例)、Ⅱ级(44例)、Ⅲ级(37例)、Ⅳ级(24例)组。另选择69例健康人作为健康对照组。比较不同组的血清CA125、BNP、hsCRP、同型半胱氨酸(Hcy)、LVEF水平及分析血清CA125与心功能及细胞因子的相关性。结果:与健康对照组比较,CHD组血清CA125、BNP、hsCRP、Hcy水平明显升高,LVEF明显下降(P<0.05或<0.01),且UAP组CA125、BNP、hsCRP较SAP组明显升高,LVEF明显下降(P<0.05或<0.01);单支、双支、多支病变组3组血清CA125、BNP、hsCRP水平逐渐升高,LVEF逐渐下降,差异均有显著性(F=5.12、6.31、7.83、5.64,P<0.05);NYHAⅠ级、Ⅱ级、Ⅲ级、Ⅳ级组血清CA125、BNP、hsCRP水平逐渐升高、LVEF逐渐下降,差异均有显著性(F=5.39、6.23、6.74、5.14,P<0.05);血清CA125水平与冠脉病变积分、病变支数,心功能级别,BNP,hsCRP呈正相关(r=0.41、0.45、0.52、0.56、0.49,P<0.05),与LVEF呈负相关(r=-0.47,P<0.05)。结论:CA125的过度分泌通过与hsCRP、BNP的相互作用可加重冠心病患者病情,恶化其心功能。     

慢性心力衰竭患者血红细胞压积与脑钠肽关系的临床观察

目的：探讨慢性心力衰竭患者的血红细胞压积（HCT）与脑钠肽（BNP）的关系。方法：入选在我院心内科治疗的非瓣膜性慢性心衰的患者110例,采用回顾性横断面研究,根据左室射血分数（LVEF）值分成3组：LVEF〈40%组（心衰Ⅰ组,37例）、40%≤LVEF〈50%组（心衰Ⅱ组,34例）和LVEF≥50%组（心衰Ⅲ组,39例）（舒张性心衰）;另选30例LVEF〉50%且无心衰症状的患者作为正常对照组,检测各组HCT和BNP水平,并进行比较分析。结果：与正常对照组患者比较,慢性心衰Ⅲ、Ⅱ、Ⅰ组患者随着LVEF水平降低,HCT[（41.1±2.7）%比（35.4±3.7）%比（32.9±1.5）%比（29.8±4.2）%]水平明显降低（P均〈0.05）,BNP[（182.3±86.8）pg/ml比（652.8±151.3）pg/ml比（874.2±201.8）pg/ml比（1342.2±325.1）pg/ml]水平明显升高（P均〈0.01）;Pearson直线相关分析显示,HCT与BNP呈负相关（R2=0.6716,P〈0.01）。结论：慢性心力衰竭患者血红细胞压积水平与心衰严重程度有关,与脑钠肽呈负相关,血红细胞压积可以作为心衰的预测指标。